Analysis of the key themes driving M&A activity reveals that regenerative medicine accounted for 3 pharmaceutical deals announced in Q1 2024, worth a total value of $5m. The $5m merger of Kadimastem and Orizuru Therapeutics was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q1 2024 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, regenerative medicine-related deal activity decreased by 100% in Q1 2024 compared with the previous quarter’s total of $2.4bn and fell by 82% as compared to Q1 2023. Related deal volume decreased by 57% in Q1 2024 versus the previous quarter.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q1 2024 – Thematic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.